Banca de QUALIFICAÇÃO: CASSIO ALEXANDRE OLIVEIRA RODRIGUES

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : CASSIO ALEXANDRE OLIVEIRA RODRIGUES
DATE: 22/10/2025
TIME: 14:00
LOCAL: meet.google.com/gnk-gvjs-osy
TITLE:

Clinical and Economic Analysis of Intravenous-to-Oral Conversion of Pantoprazole in Critically Ill Patients

KEY WORDS:

Pantoprazole; Intravenous Administration; Oral Administration; Economic Evaluation; Pharmaceutical Care

 

PAGES: 43
BIG AREA: Ciências da Saúde
AREA: Farmácia
SUBÁREA: Farmácia clínica, assistência e atenção farmacêuticas
SUMMARY:

Background: Proton pump inhibitors, widely prescribed in hospitalized patients, are frequently associated with a high number of inappropriate intravenous prescriptions, even when the oral route is suitable. Objective: To assess the economic outcomes of recommending Sequential Oral Therapy in critically ill patients receiving intravenous pantoprazole, medical acceptance of this intervention, and its effects on duration of use by route of administration, length of hospital stay, and mortality. Method: A quasi-experimental cost-minimization study conducted in a private intensive care unit (2019–2023), including 172 patients (86 in the intervention group – IG; 86 in the control group – CG). In the IG, the pharmacist recommended IV-to-oral conversion to physicians; in the CG, patients were only observed. Costs (drugs and supplies), conversion rates, and clinical outcomes were compared through univariate analysis (p < 0.05). Results: Sequential Oral Therapy was implemented in 100% of patients in the IG versus 17.4% in the CG (p < 0.001). The daily cost of oral therapy was 50-fold lower (R$ 0.23 vs. R$ 11.12; p < 0.001), resulting in a marked reduction in total cost (R$ 178.71 vs. R$ 13,959.30). Moreover, the mean duration of intravenous use was shorter (4.4 vs. 10.5 days; p = 0.001), while oral use was longer (7.1 vs. 1.5 days; p < 0.001), with no differences in mortality or length of hospital stay. Conclusion: Sequential Oral Therapy reduced costs and unnecessary intravenous pantoprazole use, with high physician acceptance and no adverse clinical impact, establishing itself as a sustainable multiprofessional strategy for pharmacotherapy optimization.

COMMITTEE MEMBERS:
Presidente - 3315645 - FRANCISCA SUELI MONTE MOREIRA
Interno - 1052612 - RODRIGO DOS SANTOS DINIZ
Externo à Instituição - FILIPE CARVALHO MATHEUS